Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy (Q74328628)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

G. S. Gerber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9507845

13 December 2024

H. L. Gornik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9507845

13 December 2024

E. R. Goldfischer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9507845

13 December 2024

G. W. Chodak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9507845

13 December 2024

D. B. Rukstalis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9507845

13 December 2024

language of work or name

English

0 references

publication date

1 April 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

April 1998

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9507845

full work available at URL

13 December 2024

http://api.elsevier.com/content/article/PII:S0022534701635729?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

http://api.elsevier.com/content/article/PII:S0022534701635729?httpAccept=text/plain

13 December 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

http://www.jurology.com/doi/pdf/10.1016/S0022-5347%2801%2963572-9

13 December 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

13 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

1243-1246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Evaluation of changes in PSA in the management of men with prostate cancer

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Results of conservative management of clinically localized prostate cancer.

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Origin and development of carcinoma in the prostate

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time

13 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(01)63572-9

13 December 2024

Identifiers

10.1097/00005392-199804000-00045

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9507845%20AND%20SRC:MED&resulttype=core&format=json